Solid Biosciences Inc. SLDB
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- +10.82%
- 1 year
- +40.13%
5D -0.44 (-6.46%)
- Market cap
- 697.57M
- EPS (ttm)
- -1.76
- Shares out
- 107.23M
- Forward P/E
- -5.46
- YTD return
- +10.82%
- 1-year return
- +40.13%
- 50-day average
- 9.32
- 200-day average
- 7.34
- Enterprise value
- 707.22M
- Volume
- 1.55M
- Avg volume
- 1.28M
- Open
- 6.29
- Previous close
- 6.44
- Day's range
- 6.20 – 6.53
- 52-week range
- 4.45 – 11.45
- Beta
- 2.44
- Analysts
- Strong Buy
- Price target
- 18.67 (+198.7%)
Key statistics
- Price / book
- 2.68
- Free cash flow
- -118.24M
- Total cash
- 377.68M
- Total debt
- 20.16M
- Return on equity
- -65.50%
- Short % of float
- 17.62%
Fundamental scorecard
4 of 25 checks passed on SLDB’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | -0.37 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.46237 | -0.38 | +0.08 | +17.81% |
| May 12, 2026 | Mar 31, 2026 | -0.40 | -0.52 | -0.12 | -30.00% |
| Mar 19, 2026 | Dec 31, 2025 | -0.51 | -0.50 | +0.01 | +1.96% |
| Nov 3, 2025 | Sep 30, 2025 | -0.42 | -0.48 | -0.06 | -14.29% |
| Aug 12, 2025 | Jun 30, 2025 | -0.51 | -0.42 | +0.09 | +17.65% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Aug 21, 2026 | Truist Securities | main | Buy | Buy |
| Jun 3, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| May 18, 2026 | Wedbush | reit | Outperform | Outperform |
| May 13, 2026 | Wedbush | main | Outperform | Outperform |
| May 13, 2026 | Piper Sandler | main | Overweight | Overweight |
About Solid Biosciences Inc.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- solidbio.com
News
Red Cat Downbeat Q3 Results, Joins Omeros, Deutsche Bank And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket
Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing Circio Enters Research Collaboration With Solid Biosciences To Evaluate Combining CircVec Generation 5 Construct With POLARIS-101 AAV Capsid For Genetic Heart Disease Gene Therapy
Solid Biosciences Says European Commission Grants Orphan Designation To SGT-212 For Treatment Of Friedreich’s Ataxia
Your note
Sign in to keep a note on SLDB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAGE CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 17, 2025 | 0 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 18, 2025 | 0 |
| BROOKS GABRIEL M.D. | Officer | Sale | Feb 17, 2026 | 89,466 |
| CUMBO ALEXANDER | Chief Executive Officer | Sale | Feb 17, 2026 | 235,405 |
| GANOT ILAN | Director | Sale | Feb 17, 2026 | 0 |
| HANRAHAN JESSIE | Officer | Sale | Feb 17, 2026 | 74,318 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 11.23% | 12,036,126 | 114.82M | Jun 29, 2026 |
| Perceptive Advisors Llc | 11.10% | 11,906,646 | 113.59M | Jun 29, 2026 |
| Bain Capital Life Sciences Investors, LLC | 9.15% | 9,808,819 | 93.58M | Jun 29, 2026 |
| Siren, L.L.C. | 7.17% | 7,690,405 | 73.37M | Jun 29, 2026 |
| Blackrock Inc. | 6.47% | 6,934,248 | 66.15M | Jun 29, 2026 |
| FMR, LLC | 6.41% | 6,875,957 | 65.60M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.94% | 3,148,576 | 30.04M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.43% | 2,606,779 | 24.87M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.37% | 2,536,385 | 24.20M | Jul 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.91% | 2,052,984 | 19.59M | Jun 29, 2026 |
| Columbia Funds Series Trust I-Columbia Small Cap Growth Fund | 1.38% | 1,476,030 | 14.08M | May 30, 2026 |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 1.17% | 1,253,978 | 11.96M | Apr 29, 2026 |
